| Literature DB >> 35838957 |
Maemu P Gededzha1,2, Nakampe Mampeule3,4, Anastasia Gandini3,4, Elizabeth S Mayne3,4,5.
Abstract
SARS-CoV-2 causes generally mild symptoms, with approximately 10-20% of cases progressing to severe disease. The pathophysiologic mechanisms by which SARS-CoV-2 causes severe disease are largely unknown. Data have indicated the involvement of different immunogenetic markers such as HLA, T, and B cells, to be associated with disease outcome. This has led to interest in these genes as potential biomarkers of SARS-CoV-2 susceptibility and for predicting prognosis and response to vaccines and other therapeutic strategies. In this chapter, we discussed outline protocols for characterizing these potential biomarkers and methods for identifying SARS-CoV-2 biomarkers using the Luminex® 100/200 technology and next-generation sequencing.Entities:
Keywords: B cell; HLA; Immunogenetic marker; Luminex; NGS; Next-generation sequencing; SARS-COV-2; T cell
Mesh：
Substances：
Year: 2022 PMID： 35838957 DOI： 10.1007/978-1-0716-2395-4_10
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745